Trending...
- "Leading From Day One: The Essential Guide for New Supervisors" Draws from 25+ Years of International Management Experience - 325
- New Slotozilla Project Explores What Happens When the World Goes Silent - 262
- Ventura College Launches County's First Speech-Language Pathology Assistant Program - 247
A novel vascular disruptive antioxidant agent for treating wet and dry AMD with potential synergy given concurrent therapies
RIVERSIDE, Calif. - Californer -- RIVERSIDE, CA – Citrus Therapeutics, LLC, a manufacturer of innovative therapies and an early leader in novel multi-pharmacophore agents for AMD treatment, announces that the U.S. Patent Office has issued Patent Application No. 17/837,917 for the "Therapeutic Agent for Treatment of Age-Related Macular Degeneration" and for the registration of the trade name "CTZ1™", the first-of-its-kind vascular disruptive agent (VDA) for treating both wet and dry AMD.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant carbazole moiety fused to a nicotine analog; this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. As a Vascular Disruptive Agent, CTZ1™ can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1 is a lead candidate for the treatment of neovascular age-related macular degeneration. To learn more about CTZ1™ as a therapeutic agent, visit our website here: citrustherapeutics.com or email salkayali@citrustherapeutics.com
CTZ1™ debuts from Citrus Therapeutics, LLC, based in Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor. Citrus Therapeutics, LLC was formed to develop, research, and promote innovative multi-pharmacophore therapies.
David RP Almeida, MD MBA PhD, is a Board-Certified Ophthalmologist and Vitreoretinal Surgeon. Dr. Almeida is involved in diagnosing and treating conditions of the vitreous, retina, and macula. Dr. Almeida is Director of Clinical Research at Erie Retina Research and Medical Director for Ophthalmology Research at The Clinical Trials Network. Dr. Almeida is Chief Medical Editor of the online publication Eyes on Eyecare, ophthalmology division.
More on The Californer
Eric K. Chin, M.D., Board-Certified ophthalmologist, is a graduate of the University of California Berkeley and Chicago Medical School. Dr. Chin was awarded several accolades for teaching and research on treatments for various retinal diseases. Dr. Chin is a partner at Retina Consultants of Southern California and serves as Clinical Faculty at Loma Linda University and Loma Linda Veterans Affairs Hospital.
Mr. Ahmad Alkayali is a renowned and trusted leader in developing and manufacturing natural ingredients for foods, beverages, and supplements. Mr. Alkayali is the original inventor of three Collagen Type II patents for dietary supplements and the first to introduce Collagen Types I, II, and III food supplements to the Health Food Industry more than 35 years ago. Mr. Alkayali's inventions and elements are incorporated into nutritional products that are recognized globally for cardiovascular, joint, skin, anti-aging, and eye health.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant carbazole moiety fused to a nicotine analog; this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. As a Vascular Disruptive Agent, CTZ1™ can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
- California: Californication of AI? Golden State is #1 in AI, and the birthplace of modern tech, so yeah — be quiet, Ted Cruz
- Premieres of 10th Annual NY Dog Film Festival & 8th Annual NY Cat Film Festival on Sunday, October 26, 2025 to Benefit Animal Lighthouse Rescue
- Inwebify Announces Launch of Scalable and Redundant Cloud Hosting Platform
- $20 Price Target in Noble Capital Research Report as Deal is Signed for NFL Yearbook Advertising Across 25 Stadiums for AI Powered Sports Leader $SEGG
- Zenni Optical Hosts Expert Panel Following the Launch of EyeQLenz™ with Zenni ID Guard™ Featuring Technology Experts Cybersecurity Girl, Judner Aura and Amber Mac
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1 is a lead candidate for the treatment of neovascular age-related macular degeneration. To learn more about CTZ1™ as a therapeutic agent, visit our website here: citrustherapeutics.com or email salkayali@citrustherapeutics.com
CTZ1™ debuts from Citrus Therapeutics, LLC, based in Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor. Citrus Therapeutics, LLC was formed to develop, research, and promote innovative multi-pharmacophore therapies.
David RP Almeida, MD MBA PhD, is a Board-Certified Ophthalmologist and Vitreoretinal Surgeon. Dr. Almeida is involved in diagnosing and treating conditions of the vitreous, retina, and macula. Dr. Almeida is Director of Clinical Research at Erie Retina Research and Medical Director for Ophthalmology Research at The Clinical Trials Network. Dr. Almeida is Chief Medical Editor of the online publication Eyes on Eyecare, ophthalmology division.
More on The Californer
- 3E Launches First AI Agent Designed to Respond with Empathy for College Recruitment
- Security Alert: TZNXG Warns Investors About "Fund Recovery" Scams
- Assent Unveils Extended Producer Responsibility Packaging Solution to Simplify Compliance with Expanding Packaging Laws
- KatalisCoin: "Too Secure" for Bad Actors - Platform Embraces "Excessive Compliance" Criticism
- Blacksmith Raises $10M to Unblock AI Development with Fast CI for GitHub Actions
Eric K. Chin, M.D., Board-Certified ophthalmologist, is a graduate of the University of California Berkeley and Chicago Medical School. Dr. Chin was awarded several accolades for teaching and research on treatments for various retinal diseases. Dr. Chin is a partner at Retina Consultants of Southern California and serves as Clinical Faculty at Loma Linda University and Loma Linda Veterans Affairs Hospital.
Mr. Ahmad Alkayali is a renowned and trusted leader in developing and manufacturing natural ingredients for foods, beverages, and supplements. Mr. Alkayali is the original inventor of three Collagen Type II patents for dietary supplements and the first to introduce Collagen Types I, II, and III food supplements to the Health Food Industry more than 35 years ago. Mr. Alkayali's inventions and elements are incorporated into nutritional products that are recognized globally for cardiovascular, joint, skin, anti-aging, and eye health.
Source: Citrus Therapeutics
Filed Under: Health
0 Comments
Latest on The Californer
- Who Will Win the 2025 WNBA Finals? OddsTrader Shares Live Betting Odds and Projections
- Silva Construction Weighs In on the Most Popular Home Design Trends for 2026
- Geeks5g Creative Marketing: The Powerhouse Behind Business Growth
- Wise Business Plans Now Serves Entrepreneurs in Los Angeles with Tailored Business Plan Writing
- Proposition 1 continues delivering support for vulnerable homeless populations in California
- Agemin Unveils Breakthrough AI Model for Biometric Age Estimation, Setting New Standards in Online Child Safety
- Turnout Secures $21M in Seed Funding to Fuel Mission to Simplify Government Bureaucracy
- Teamsters Local 2010, UC Labor Unions File Historic Lawsuit Against Trump Administration
- Strategic Partnerships with Defiant Space Corp and Emtel Energy USA Powerfully Enhance Solar Tech Leader with NASA Agreements: Ascent Solar $ASTI
- 120% Revenue Surge with Four Straight Profitable Quarters Signal a Breakout in the Multi-Billion Dollar Homebuilding Market: Innovative Designs $IVDN
- Leading Venture Capital Firms Recognize Wzzph Exchange's Technical Architecture and Security Framework as Industry Benchmark
- DivX Unveils Major DivX Software Update: Seamless Video Sharing and Customizable Playback Now Available
- Zoiko Supply Group Named Exclusive Distributor of Taj Mahal Rice in Caribbean, LATAM& African Market
- Software VS Paid Newsletter for Creating Side Income
- Nespolo Mechanical Helps New Mexico Families Save Thousands on Heating Costs This Fall
- Leading Digital Finance Platform YNQTL Launches Revolutionary Web3 Digital Asset Trading Platform
- Venbrook and Cognizant Partner to Modernize Claims Processing for Insurance Carriers
- IDCXS Addresses Crypto Trading Pain Points with 2 Million TPS Processing and Multi-Layer Security Architecture
- Dr. Richard Austin Heafey, PsyD, of Unfold Psychology and Heafey Practices, Accused of Misconduct
- Bridging Traditional Finance and Web3 Innovation: BLFCW Announces Strategic Vision for Regulated Web3 Economy